Cambrex reported a sales decline of 2.8% in Q1 2009. The company said that excluding currency impacts sales increased 8.7% primarily due to long standing orders of two APIs, higher volumes of controlled substances and slightly higher custom development revenues. However, the company saw lower sales of generic APIs.
Cambrex
Wednesday, 6 May 2009
Cambrex sales decline
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment